MDL 3014 — formally In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation — is pending in the U.S. District Court for the Western District of Pennsylvania under docket 2:21-mc-01230-JFC. Chief Judge Joy Flowers Conti has been the presiding judge since the MDL's formation in October 2021, with Magistrate Judge Patricia L. Dodge handling discovery matters. Pittsburgh was selected as the MDL venue in part because Philips Respironics is headquartered in nearby Murrysville, Pennsylvania.
The MDL entered 2026 with general causation Daubert hearings and bellwether trial scheduling as the primary litigation drivers. Philips has aggressively challenged plaintiffs' expert witnesses on the causal link between foam VOC exposure and specific cancer diagnoses. Court rulings on Daubert motions — either admitting or excluding plaintiffs' causation experts — will be the single most important development in determining settlement pressure and timeline. The Zantac MDL's 2022 dismissal (after causation experts were excluded) is Philips's blueprint; CPAP's direct chemical evidence is considered significantly stronger.
Frequently Asked Questions
Related Pages
The carcinogenic chemicals released by degraded Philips CPAP foam are linked to cancers of the nasopharynx, throat, lungs, kidneys, liver, bladder, and thyroid. Nasopharyngeal cancer is the most prevalent diagnosis among MDL 3014 plaintiffs due to direct foam exposure through the breathing pathway.
Learn moreCPAP cancer claimants can pursue compensation for medical expenses, pain and suffering, lost wages and earning capacity, disability, and wrongful death damages. Projected individual amounts range from $20,000 for non-cancer injury to over $3 million for wrongful death — final amounts depend on the global MDL settlement structure.
Learn moreThe Philips DreamStation — including DreamStation CPAP, Auto CPAP, BiPAP, DreamStation Go, and DreamStation ASV — is the most common recalled device among plaintiffs in MDL 3014. DreamStation users who developed cancer after using the device have among the strongest factual profiles for a CPAP cancer claim.
Learn moreThe strongest CPAP cancer claims have three evidence pillars: proof of device use (receipts, CPAP prescriptions, insurance records), cancer diagnosis documentation (pathology reports, oncology records), and exposure documentation (device model/serial number, ozone cleaner records, use duration). Missing some of these is common — an attorney can help you obtain records.
Learn moreMost states have 2-year statutes of limitations for CPAP cancer lawsuits. The discovery rule starts the clock when you knew your cancer was linked to your device — but windows are narrowing. Contact an attorney immediately to protect your right to sue.
Learn moreNasopharyngeal cancer (NPC) is the most prevalent cancer diagnosis among plaintiffs in MDL 3014. The nasopharynx receives direct chemical exposure from PE-PUR foam degradation byproducts during CPAP use — the clearest anatomical link between device use and cancer development. If you were diagnosed with NPC after using a recalled Philips CPAP, you have one of the strongest potential claims in the MDL.
Learn moreThe polyester-based polyurethane (PE-PUR) foam used as a sound abatement material inside Philips CPAP devices degrades under heat, humidity, and ozone exposure, releasing over 200 chemical compounds — including known and suspected human carcinogens — directly into the breathing pathway. This is the central mechanism of the Philips CPAP cancer litigation.
Learn morePhilips issued a Class I recall of 15 million CPAP and BiPAP devices in June 2021 after PE-PUR foam was found to release cancer-causing chemicals when it degrades. If you used a recalled device, you may have a legal claim even if you haven't been diagnosed with cancer.
Learn moreThe Philips recall covers CPAP, BiPAP, and ventilator devices manufactured between approximately 2009 and 2021. The DreamStation is the most common plaintiff device. If you used any Philips Respironics device with PE-PUR foam insulation before June 2021, it is very likely recalled.
Learn moreNo global settlement has been announced in MDL 3014 as of early 2026. Attorney projections based on comparable MDL outcomes range from $20,000 for documented non-cancer injuries to $3,000,000+ for wrongful death claims. Your cancer type, stage, device use duration, and documentation quality all affect your case value.
Learn moreSymptoms of PE-PUR foam chemical exposure range from immediate irritation (headaches, throat irritation, nausea) to serious cancer warning signs (unexplained weight loss, persistent cough, blood in urine, neck lumps). If you used a recalled device and have any of these symptoms, see a doctor and contact an attorney immediately.
Learn moreCPAP Cancer Lawsuit
The 2021 Philips CPAP recall — one of the largest in medical device history — exposed millions of users to carcinogenic foam particles and VOCs. Cancers linked to exposure include nasopharyngeal, lung, kidney, liver, and bladder cancer. MDL 3014 in Pittsburgh is advancing toward bellwether trials in 2026.
View full case overview